Lobbying client
GALEPHAR PHARMACEUTICAL RESEARCH INC.
Pharmaceutical manufacturing
Filings
3
Filed by
1
Reported in-house
—
Reported by firms
$20,000
Filings
3 filings, newest first.
| Filing | Filed by | Amount |
|---|---|---|
|
3rd Quarter - Termination (No Activity) 3rd Quarter 2021
|
BUCHANAN INGERSOLL & ROONEY PC | — reported |
|
2nd Quarter - Report 2nd Quarter 2021
|
BUCHANAN INGERSOLL & ROONEY PC | $20,000 reported |
|
Registration 2nd Quarter 2021
|
BUCHANAN INGERSOLL & ROONEY PC | — reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| BUCHANAN INGERSOLL & ROONEY PC | 2 | $20,000 |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Health Issues | HCR | 2 |
| Pharmacy | PHA | 2 |
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.